RELATED STUDY

Key Findings: 

Type of Study: 

Study Result:  Inconclusive

Research Location(s): 

Year of Pub: 


Cannabinoids Studied: 

Chemotype: 

Terpenes Studied: 

Receptors Studied: 

Ligands Studied: 

DOSING DETAILS   

Study Dosing Objective:  Effective Dose,

Established Protocol:  Effective dose

Route of Administration: 

Cannabinoid Ratio:  (THC : CBD)   19 : 9    

Dosage Form:  19% THC or 19% THC with 9% CBD

Dosing Regimen:  200 mg was effective in reducing migraine pain by 55% 200 mg of THC with CBD was superior to amitriptyline

Adverse Events:  Somnolence with an edible form of medical cannabis. 23.1% in one study reported adverse effects, and 1.3% of those cases discontinued medical cannabis, but no severe adverse effects were reported.




Citation: